Phase 2 Trial Reaches 50% Recruitment
Syntara has reached the 50% recruitment milestone in its Phase 2 trial evaluating SNT-5505, in combination with ruxolitinib, treating the bone marrow…
Read more
Recent highlights
SNT to trial new cancer indication following MRFF grant
Syntara has added a new blood cancer indication to the clinical development plans for its drug discovery SNT-5505. The drug will be…
Syntara completes two-tranche placement of A$10m
Syntara completes A$10.0 million via a two-tranche placement at $0.022 per share. The Company completes Share Purchase Plan (SPP) that provided all…
First patient dosed in Phase 2 bone marrow cancer trial of SNT-5505 in combination with ruxolitinib.
The combination therapy study is recruiting patients from 19 clinical trial sites in Australia, South Korea, Taiwan and the USA. It follows…
Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease
Syntara has announced the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug…
Sale of mannitol respiratory business and launch of Syntara
Pharmaxis has announced details of the sale of its mannitol respiratory business which manufactures and supplies Aridol and Bronchitol to global markets…
Syntara has reached the 50% recruitment milestone in its Phase 2 trial evaluating SNT-5505, in combination with ruxolitinib, treating the bone marrow cancer myelofibrosis. Recruitment for the open-label study commenced in December 2023 with the 8th patient in the 15-patient trial dosed earlier this week, keeping Syntara on track for completion of recruitment by the…
Syntara has added a new blood cancer indication to the clinical development plans for its drug discovery SNT-5505. The drug will be trialled along with chemotherapy in patients with low and intermediate risk of myelodysplastic syndrome (MDS). The trial, which has attracted a government research grant, will commence later this year and will be led…
Syntara completes A$10.0 million via a two-tranche placement at $0.022 per share. The Company completes Share Purchase Plan (SPP) that provided all eligible shareholders the opportunity to participate in the transaction. Funds raised will be used towards completion of three Phase 2 clinical trials in myelofibrosis, scarring and iRBD/Parkinson’s disease as well as for general…
First patient dosed in Phase 2 bone marrow cancer trial of SNT-5505 in combination with ruxolitinib.
The combination therapy study is recruiting patients from 19 clinical trial sites in Australia, South Korea, Taiwan and the USA. It follows results from an earlier cohort demonstrating SNT-5505 had an excellent safety profile and encouraging signs of efficacy when used in patients who had failed on current standard of care. Watch a Proactive interview…
Syntara has announced the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease. The study will examine whether targeting inflammation in the brain of people with…
Pharmaxis has announced details of the sale of its mannitol respiratory business which manufactures and supplies Aridol and Bronchitol to global markets and the formation of Syntara, a clinical stage drug development company primarily focusing on treatments for haematological malignancies (blood-related cancers). In a major restructure the mannitol business will be sold to pharmaceutical manufacturing…
The prestigious journal Nature Cancer has published preclinical results showing Pharmaxis’ pan-Lysyl Oxidase (pan-LOX) inhibitor PXS-5505 increases survival by 35% compared to chemotherapy treatment alone in the treatment of pancreatic ductal adenocarcinomas. Research in mouse models, led by a team at the Garvan Institute of Medical Research also showed PXS-5505 combined with chemotherapy reduced the…
Final set of interim data from PXS-5505 trial in 10 patients treated for 6 months demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity. Read more here. Watch an interview with CEO Gary Phillips here.
Pharmaxis’ novel topical drug treatment for scarring has achieved encouraging results from a phase 1c showing marked change in scar composition with 30% reduction in collagen content. The study of LOX inhibitor PXS-6302 is being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM. The study aims to…
Pharmaxis Cancer Drug Doubles Response Rate to Standard Therapy in Blood Cancer Pre Clinical Studies
Nature communications publishes peer-reviewed data from highly predictive pre clinical models using cells from mylodysplastic syndrome patients. Best in class results from combination of pxs-5505 and standard of care demonstrates a strong rationale for treatment of several blood cancers. Read more here.